European drug regulators have turned a temporary restriction on Pfizer’s Xeljanz into a formal one.
In a decision posted Friday, the European Medicines Agency said the immunology drug's 10-mg twice-daily maintenance dose should not be used in ulcerative colitis patients at high risk of blood clots unless there’s no alternative.
Copyright © 2020,